Results 121 to 130 of about 36,129 (239)
Graphical abstract summarizing evidence that dissecting cellulitis of the scalp (DC) and hidradenitis suppurativa (HS) may represent site‐modified expressions of a shared follicular‐occlusion pathway, highlighting convergent clinical, histopathologic, and therapeutic features, the diagnostic‐context paradox, and the need for paired molecular studies ...
Giuseppe Gallo +6 more
wiley +1 more source
Secukinumab and Adalimumab on Bone Health in Psoriasis: A Longitudinal Cohort Study. [PDF]
Yu C +9 more
europepmc +1 more source
Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis +54 more
wiley +1 more source
Methotrexate's effect on cells and adalimumab immunogenicity in axial spondyloarthritis: A mathematical study. [PDF]
Sottile S +5 more
europepmc +1 more source
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos +9 more
wiley +1 more source
A Practical Roadmap for Implementing the LC-MS-Based Multi-Attribute Method for Analysis of Therapeutic Proteins. [PDF]
Guo J +8 more
europepmc +1 more source
Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Fabià Torres‐Betato, Lluís Puig
wiley +1 more source
Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II
The majority of bimekizumab‐treated patients shifted from severe to mild and moderate IHS4 stages, and nearly 25% achieved an IHS4 of 0 by Week 48. Bimekizumab led to clinically meaningful improvements across IHS4 outcome measures. These data highlight an opportunity to address the need for effective treatments against draining tunnels.
Thrasyvoulos Tzellos +15 more
wiley +1 more source
Impact of Nonmedical Adalimumab Switches in a Rheumatology Patient Population. [PDF]
DelPrete S +6 more
europepmc +1 more source
HPV125‐induced generalized verrucosis
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Sven Niklas Burmann +7 more
wiley +1 more source

